Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x100px

Organisation › Details

Owlstone Medical Ltd.

https://www.owlstonemedical.com

LinkedIn: https://www.linkedin.com/company/owlstone

Owlstone Medical has developed a unique breathalyzer for disease. The company’s vision is to become the global leader in non-invasive breath tests for early disease detection and precision medicine across cancer, inflammatory disease and infectious disease with the aim of saving 100,000 lives and $1.5 billion in healthcare costs. Owlstone Medical’s Breath Biopsy® platform is creating a new industry category, based on the routine detection and analysis of volatile organic compound (VOC) biomarkers in breath, which has the potential to revolutionize healthcare. The award winning ReCIVA Breath Sampler is the first standardized breath collection device designed to capture the VOC biomarkers present in breath, which are then analyzed using Owlstone Medical’s Breath Biopsy services and products. Owlstone Medical is developing breath tests for the early detection of lung and colorectal cancer. These are two of the most common cancer killers worldwide and represent multibillion dollar market opportunities. The company has an active clinical diagnostics/screening pipeline including the world’s largest breath-based clinical trials. The Breath Biopsy platform is also being deployed in the PAN cancer trial, a collaboration with Cancer Research UK studying the early detection of eight different cancer types in breath. The company also sees a significant role for Breath Biopsy in precision medicine, where it can provide dynamic information about a patient’s disease activity and identify patients most likely to respond to a particular therapy. Breath Biopsy aims to ensure that the right therapy is given to the right patient at the right time, helping to improve patient outcomes and reduce healthcare costs. Owlstone Medical’s Breath Biopsy clinical laboratory is a unique, revenue generating capability that allows pharmaceutical, clinical and academic partners worldwide to explore breath-based biomarkers to optimize their own precision medicine activities. The commercialization of Breath Biopsy precision medicine companion diagnostics through pharmaceutical partners is expected to provide Owlstone Medical with a significant royalty stream as breath-based precision medicine becomes a reality. Owlstone Medical was spun out of Owlstone Inc. in 2016 to develop and commercialize medical applications of its proprietary microchip chemical sensing technology, Field Asymmetric Ion Mobility Spectrometry (FAIMS), which is sold in the military and industrial sectors globally. The company has raised a total of $38.5 million in equity financing, and is backed by technology investor Horizons Ventures, and Aviva, a leading healthcare insurer. Owlstone Medical is headquartered in Cambridge, UK. *

	Start	2016-01-01 established (s-off)
	Group	Owlstone (Group)
	Predecessor	Owlstone Inc.
	Industry	FAIMS technology
	Industry 2	Breathalyzer
	Person	Boyle, Billy (Owlstone 201606 CEO + Co-Founder of Owlstone Medical Ltd)
	Person 2	Toumazou, Christofer (Chris) (DNA Electronics 201011 CEO)

	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Milton Road Cambridge Sciencde Park, 162
	City	CB4 0GH Cambridge, Cambridgeshire
	Tel	+44-1223-428200
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2024-01-20

Top News

Upcoming Events

Management Appointments

Financings & Acquisitions

Collaborations & Licensing

At Investor Conferences

Associations

Advertise

Owlstone Medical Ltd.

More documents for Owlstone (Group)